Monday, October 5, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 5, 2026

B2B Payments Global Report 2025: A 15.88 Trillion Market by 2030 from $11.69 Trillion in 2024 with Citi TTS, JP Morgan, HSBC Global, Visa, and Mastercard Accounting for 29.2% Share

View original at finance.yahoo.com
B2B Payments Global Report 2025: A 15.88 Trillion Market by 2030 from $11.69 Trillion in 2024 with Citi TTS, JP Morgan, HSBC Global, Visa, and Mastercard Accounting for 29.2% Share Company Logo Open Banking, AI/ML, and digital finance platforms are transforming B2B payments…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The continued digitization of enterprise finance and expansion of scalable payment infrastructure are expected to sustain long-term growth in the B2B payments market

    80% confidence

  • The B2B payments market will grow at a CAGR of 5.2% from 2024 to 2030

    80% confidence

  • Asia-Pacific and Latin America are the fastest-growing regions during the forecast period

    80% confidence

  • Citi TTS, JP Morgan, HSBC Global, Visa, and Mastercard together accounted for 29.2% of total market revenue in 2024

    80% confidence

  • SMEs are emerging as a key growth engine for the B2B payments market, particularly in regions with developing financial infrastructure

    80% confidence

  • North America and Europe accounted for the largest share of global B2B payments value in 2024

    80% confidence

  • The B2B payments market is projected to reach USD 15.88 trillion by 2030

    80% confidence

  • There are 61 major B2B payments providers globally

    80% confidence

  • The global B2B payments market was valued at USD 11.69 trillion in 2024

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com